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ABSTRACT
Hepatitis C is a major public health concern, with
an estimated 170 million people infected worldwide
and an urgent need for new drug development.
An attractive therapeutic approach is to prevent the
‘cap-independent’ translation initiation of the viral
proteins by interfering with both the structure and
function of the hepatitis C viral internal ribosomal
entry site (HCV IRES). Towards this goal, we report
the design, synthesis and purification of novel
bi-functional molecules containing DNA or RNA
antisenses attached to functional groups perform-
ing RNA hydrolysis. These 5’ or 3’-coupled con-
jugates bind the HCV IRES with affinity and
specificity and elicit targeted hydrolysis of the viral
genomic RNA after short (1 h) incubation at low
(500nM) concentration at 37uC in vitro. Additional
secondary cleavage sites are induced and their
mapping within the RNA structure indicates that
functional domains IIIb-e are excised from the IRES
that, based on cryo-EM studies, becomes incapable
of binding the small ribosomal subunit and initiation
factor 3 (eIF3). All these molecules inhibit, in a dose-
dependent manner, the ‘IRES-dependent’ transla-
tion in vitro. The 5’-coupled imidazole conjugate
reduces viral protein synthesis by half at a 300nM
concentration (IC50), corresponding to a 4-fold
increase of activity when compared to the naked
oligonucleotide. These new conjugates are now
being tested for activity on infected hepatic cell lines.
INTRODUCTION
The hepatitis C virus (HCV) belongs to the Flaviviridae
family, with a positive single-strand RNA genome.
An estimated 170 million people are infected worldwide.
Most will develop chronic hepatitis, some with severe
complications including liver failure or hepatocellular
carcinoma (1). Despite clinical improvements allowed by
the combination of interferon-alpha and ribavirin, this
therapeutic approach fails in about half the patients (2).
The HCV virus possesses high genomic plasticity and
drug-resistant viruses emerge under pharmacological pres-
sure. Ongoing drug development includes novel protease
and RNA polymerase inhibitors, as well as immuno-
modulators but there is no vaccine against HCV yet.
Cap-dependent eukaryotic protein synthesis is a sophis-
ticated mechanism requiring the association of numerous
initiation factors at the 50-end of the capped mRNA.
Active 80S ribosomes are formed after message scanning
by the 40S subunit to ﬁnd an AUG initiation codon for
placing the initiator tRNA (3). In the case of HCV
genomic RNA, translation initiation is triggered by a
‘cap-independent’ mechanism involving its 50 and
30-untranslated regions (UTRs). Correct positioning of
the ribosomes from infected cells onto the internal viral
AUG codon requires two initiation factors, eIF2 and
eIF3. For the HCV RNA translation, as for prokaryotic
translation initiation, there is no scanning but the process
needs a structured sequence at the genomic RNA 50-end
called an Internal Ribosome Entry Site [IRES, (3,4)].
The HCV IRES is a 340 nt-long RNA motif encom-
passing four structural domains (I–IV, Figure 1). Unlike
most of the primary sequence of the HCV genome, the
IRES nucleotide sequence is highly conserved among all
the genotypes (5), suggesting its importance for the virus
life cycle (6–8). Its secondary structure was deduced from
comparative sequence analysis and structural mapping (9).
Domain I is a short hairpin, domain II is a long inter-
rupted stem with internal bulges, domain III contains ﬁve
stem–loops, denoted ‘a to e’ with a four-way junction,
abutting to a pseudoknot. Domain IV is a short stem–loop
with the AUG start codon embedded within the loop.
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Structures of the isolated domains II, IIId and IIIe were
determined by NMR spectroscopy and/or X-ray crystal-
lography (10–12). As revealed by ‘footprinting/toeprint-
ing’ experiments (13) and by cryo-electron microscopy
(14,15), the HCV IRES forms a binary complex with the
40S ribosomal subunit thanks to direct interactions with
domains II and III. Domain II is bended and forms an
angle between IIa and IIb (14). It loops away from the
40S, inducing contacts with a region next to the E-site
thanks to subdomain IIb. Domain III contacts the
platform of the 40S and interacts simultaneously with
initiation factor eIF3 (16).
There are growing interests in developing new drugs
targeting HCV viral genome, with some emphasis to the
IRES that is indispensable for virus survival. Domains II
and III are reasonable candidates to design molecules that
interfere with initiation complex assembly, preventing
viral protein synthesis. Pathogenic RNAs involved in
acute and chronic infectious diseases can be selectively
inactivated by various pharmacological compounds (17),
including modiﬁed nucleic acids. Among those, antisense
oligonucleotides, ribozymes, small interfering- or micro-
RNAs do receive a particular attention at the present
time (18). As recent examples, several RNA or DNA
aptamers have been selected against domains II and IIId
of the HCV IRES and they decrease viral translation up
to 90% in vitro and/or in vivo (19–22). Also, modiﬁed
oligonucleotides, peptide nucleic acids (PNAs) and
siRNAs inactivate domains II or IIId of the HCV IRES
in vitro and in vivo (20–28). An antisense oligonucleotide
targeting domain II of HCV IRES is currently tested in a
phase-one trial (29).
Among the compounds capable of RNA hydrolysis,
imidazole moieties are RNase A catalytic centre mimics
(30–32). The ‘imidazole-catalyzed’ RNA hydrolysis,
however, requires long incubation periods and millimolar
concentrations to cleave target RNAs (33,34). We showed
previously that polyamine-imidazole conjugates induce
non-random, site-selective RNA scission, even with a
single imidazole moiety (35). However, polyamines bind
RNAs with low speciﬁcity and such conjugates become
active at millimolar concentrations and require long
incubations (10–15 h) with the RNA substrates.
In this report, we describe the design, synthesis,
puriﬁcation and testing of novel nucleic acids conjugates
that cleave the HCV IRES genomic RNA at speciﬁc
locations and decrease, in a dose-dependent manner,
the ‘IRES-mediated’ in vitro translation of reporter
proteins. The antisense nucleotide sequence was inspired
from an RNA aptamer identiﬁed by in vitro selection, that
binds domain IIId of the IRES RNA from HCV and
inhibits IRES-dependent in vitro translation (21). These
conjugates contain various RNase A catalytic centre
mimics, each attached to either the 50 or the 30 end of
selected DNA oligonucleotides that can pair speciﬁc
RNA sequences (domain IIId) from the HCV IRES
RNA genome. This novel set of bi-functional RNA-
cleaving molecules recognizes and cleaves the targeted
RNA sequences with speciﬁcity and eﬃciency.
These conjugates are active at low (500 nM) concentra-
tions, require short (<1 h) incubation times and inhibit
IRES-dependent translation in vitro in a dose-dependent
manner. These novel molecules capable of directed
degradation of a functional domain of the HCV genomic
RNA are now being tested for antiviral activity and
toxicity on infected hepatic cell lines.
MATERIAL AND METHODS
Synthesis of oligonucleotide conjugates
The chemicals were purchased by Sigma–Aldrich (St Louis,
USA). Dihydrourocanic acid was obtained by catalytic
hydrogenation of urocanic acid in methanol (10% Pd/C)
followed by crystallisation in ethanol as previously
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Figure 1. Secondary structure of the IRES from the HCV genomic
RNA deduced from comparative sequence analysis and structural
mapping (9). Nucleotides are numbered every 20 nt and the major
structural domains (I to IV) are indicated. The predicted binding site of
the 17-mer antisense oligonucleotide within the IRES sequence is
indicated. The arrow points to the ribose-phosphate bond that is
hydrolysed by the 50-coupled imidazole oligonucleotide conjugate 1.
The three numbered stars indicate the position of the secondary
cleavage sites triggered by oligonucleotide conjugates 1 and 4 within
domains IIIb and IIIe. The AUG translation initiation codon of the
viral genomic RNA is grey-boxed.
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described (36). All the oligonucleotides were assembled by
Eurogentec (Lie`ge, Belgium). The following DNA oligo-
nucleotide was used to target the IIId domain:
50-ACCCAACACTACTCGGC-30 (AS), it was either
non-modiﬁed or bearing a C3-amino group at the 50- or
30-end. Its 20-O-methyl RNA analogue (50-ACCCAACA
CUACUCGGC-30 RNA_AS) was also synthesized with a
C3-amino group at the 50 end. A non-speciﬁc DNA
oligonucleotide (NS: 50-CAACCCTAGCCCGTCAA-30),
scrambled from the original sequence, was also synthesized.
The procedure for coupling the amino-oligonucleotides
(Figure 2) was adapted from (37). 30 mmol (1 eq) of acid
RCO2H were activated during 150min under argon with
1.2 eq of PyBOP, 1.5 eq of HOBT and 3 eq of freshly dried
N-methylmorpholine in 1ml of dry DMF. Fifty micro
liters of this solution were added to 40 nmol of the amino-
oligonucleotide in 150 ml of buﬀer (133mM NaHCO3/
Na2CO3, pH 9). One hour later, 50 ml of the activated ester
were added to the oligonucleotide solution. This addition
was repeated four times. The mixture was kept overnight
at room temperature. Prior to analysis and puriﬁcation,
the oligonucleotides were precipitated with 0.1 vol of 3M
sodium acetate (pH 5.3) and six volumes of absolute
ethanol. The pellets were dissolved in 100ml of water.
DNA concentration was assessed by UV measurement at
260 nm. The coupling protocol was the same for the DNA
amino-oligonucleotide and its 20-O-Me-RNA analogue.
The oligonucleotide conjugates were analysed and
puriﬁed by reverse phase HPLC on Uptisphere ODB
C18-5m columns (Interchim, France) using an ISS200 LC
system (Perkin Elmer, USA). The ﬂow rate was 1ml/min
for analytical purpose (250 4.6 column) and 3ml/min. for
quantitative puriﬁcation (250 10 column). The following
sequence was used: after 5min elution with 25mM TEAA
(pH 7.0), a linear gradient from 0 to 15% of acetonitrile in
25mM TEAA was applied for 15min. It was followed
by elution with 15% acetonitrile in TEAA for 10min.
Retention times of the antisense oligonucleotides were,
respectively, 20.2min for the amino-oligonucleotides (50 or
30) and 20.5min for the corresponding conjugate. No
signiﬁcant diﬀerence could be observed between the
retention times of the various imidazole-coupled oligonu-
cleotides (Figure 2). For the 20-O-Me-RNA antisense, the
following sequence was used: after 5min elution with
25mM TEAA (pH 7.0), a linear gradient from 0 to 30% of
acetonitrile in 25mMTEAAwas applied for 30min. It was
followed by elution with 30% acetonitrile in TEAA for
10min. Retention times of the antisense RNA oligonucleo-
tides were respectively 27.5min for the amino-20-O-Me-
RNA oligonucleotide and 27.8min for the corresponding
conjugate (5). Monitoring was performed at 260 nm. After
HPLC puriﬁcation and precipitation, the ﬁnal yield of
conjugate formation is close to 50%. The puriﬁed
oligonucleotide conjugates were analysed by MALDI-
TOF mass spectrometry using an Ultra Flex Mass
Spectrometer (Bruker Daltonics, Germany). For each
molecule synthesized, the measured mass was in accor-
dance to the theoretically calculated value.
Plasmids preparation
Bicistronic pIRF HCV (5) and pIRF ECMV
(EnCephaloMyocarditis Virus) were both digested by
BamH1 and Kpn1 restriction enzymes to extract the
Firefly luciferase coding sequence. After ligation of the 50
and 30 ends by the Klenow fragment of DNA Polymerase
1 from Escherichia coli, we obtained the monocistronic
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Figure 2. Chemical procedure used to couple the functional groups to the 50 or to the 30-ends of the DNA oligonucleotide. The activated ester was
added to the amino-oligonucleotide (DNA or 20-O-Me-RNA oligonucleotide) to form a peptide bond. The imidazole-conjugated oligonucleotides
were obtained from dihydrourocanic acid. The DNA amino-oligonucleotide was coupled either at the 50 or the 30-end, they are respectively
denoted 50-imidazole (50-Im, 1) and 30-imidazole (30-Im, 4). The imidazole-coupled 20-O-Me-RNA oligonucleotide, denoted 50-imidazole_RNA
(50-Im-RNA, 5), was coupled at the 50-end. Urocanic acid and benzimidazoleacetic acid functional groups were also coupled at the 50-end of the
DNA oligonucleotide. The corresponding oligonucleotides are respectively denoted 50-UA (2) and 50-BI (3).
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plasmids pIRF_HCV-RLuc and pIRF_ECMV-RLuc
coding for the reporter gene of Renilla luciferase under
the control of each of the IRES sequences. The integrity of
the coding genes sequences was veriﬁed by sequencing the
plasmid.
In vitro transcription
HCV_IRES-RLuc and ECMV_IRES-RLuc DNA tem-
plates used for the in vitro translation assays were
produced after the linearization of plasmids pIRF by
BstX1. The HCV_IRES DNA template was produced
from the pUC19 plasmid linearized by BamH1. All these
DNA sequences were puriﬁed by phenol/ether extraction
and ethanol precipitated. RNAs were synthesized for
4 h using the T7 Megascript Kit (Ambion, USA) and
puriﬁed with MegaClear columns (Ambion, USA).
RNAs and oligonucleotides labelling
The HCV IRES RNAs were labelled at their 30-ends using
T4 RNA ligase (New England Biolabs, USA) and
Cytidine 30,50-Bis32Phosphate (32pCp). The radiolabelled
RNAs were loaded onto a 6% polyacrylamide/bisacryla-
mide (19:1) 8M urea denaturing gel in TBE buﬀer [90mM
Tris–borate, 2mM EDTA (pH 8) at 208C]. The electro-
phoresis was performed at 30V/cm for 3 h. The band
corresponding to the intact RNA was excised and eluted
for 8 h at 378C in 20mM HEPES (pH 7.5), 250mM NaCl,
1mM EDTA, 1% SDS. The RNA was ethanol precipi-
tated and the pellets were dried and aliquoted at –208C.
The RNA was stored in 10mM HEPES (pH 7.5) prior to
use. Both the naked oligonucleotides and the 30-coupled
oligonucleotides were labelled at their 50 ends using T4
Polynucleotide kinase (New England Biolabs, USA)
and [g-32P] ATP. The 50-coupled oligonucleotides were
labelled at their 30-ends using Terminal Deoxynucleotidyl-
Transferase (Promega, France) and [a-32P]-UTP.
IRES refolding
Before all the experiments, the IRES RNAs were heated
for 2min at 808C in folding buﬀer (10mMHEPES pH 7.5,
20mM NH4Cl and 3mMMgCl2) and slowly cooled down
at room temperature for 30min.
Native gel retardation assays
One picomole of each of the labeled antisense oligonu-
cleotides was incubated for 15min at 378C in 10 ml of
10mM spermidine, 80mM HEPES (pH 7.5), 200mM
NH4Cl, 3mM MgCl2 with increasing concentrations of
refolded IRES RNAs (from 10 to 2000 nM). Samples
were loaded onto a 5% acrylamide/bisacrylamide (37.5:1)
gel in TBM buﬀer [45mM Tris–borate (pH 8.3), 0.2mM
MgCl2] at 300V (8V/cm, 3W) for 2 h 30min. The
percentage of oligonucleotides bound to the IRES
RNAs was determined as the ratio of radioactivity
measured in the RNA/oligonucleotide complex to the
total amount of radioactivity measured in the lane. Bands
corresponding to the RNA–conjugate duplexes and to
the unbound oligonucleotide were quantiﬁed using
‘ImageJ’ (38).
IRES cleavage reactions
Refolded 30-end labelled IRES transcript measuring
100 000 c.p.m. (0.1 pmol) were incubated for 1 h at
378C with increasing concentrations (from 0.5 to 50 mM)
of either naked or conjugated oligonucleotides in 10 mL of
cleavage buﬀer (1.5mM MgCl2, 150mM NaCl, 50mM
HEPES pH 7.5, 10 mM ZnSO4). Reactions were quenched
by RNA precipitation in 20 mL of 0.3M sodium acetate
(pH 5.3) and 400 mL of 2% lithium perchlorate (diluted in
acetone). The pellets were dissolved in loading buﬀer
(80% formamide, 10mM EDTA pH 8.0, 0.1% xylene
cyanol, 0.1% bromophenol blue) and the samples loaded
onto denaturing gels (7% acrylamide/bisacrylamide
(19:1), 8M urea, TBE 1). Both the digestions with
RNase T1 (Amersham, USA), RNase U2 (Pierce
Nucleic Acids Technologies, USA) and the alkaline
hydrolysis were performed in parallel in order to map
the cleavage sites.
RNase H cleavage assays
Radiolabelled IRES RNA 100 000 c.p.m. (0.1 pmol) was
annealed with 50 pmol of antisense oligonucleotide.
RNase H cleavage assays of the labelled oligonucleo-
tides/IRES complexes were then performed by incubating
1U of RNase H (USB Corporation, USA) for 45min
at 378C in 10 ml of a solution containing 1mM DTT,
10mM MgCl2, 160mM KCl, 64mM H (pH 7.5) and
8mM spermidine. The samples were loaded onto a 7%
polyacrylamide denaturing gel. Both the concentration
and the incubation time of the oligonucleotide conjugates
were selected, on purpose, suﬃciently low so that they
do not trigger RNA hydrolysis.
IRES translation assays in the presence of the conjugates
In vitro translation assays were performed using cell-free
translation assay [Rabbit Reticulocyte Lysates, Nuclease-
treated (Promega, France)]. Reactions were performed
by adding ﬁrst each oligonucleotide conjugate (from
200 nM to 5 mM ﬁnal concentration) to 0.2 mg of Renilla
Luciferase-driven IRES RNA. Reticulocyte lysate
was then added straight ahead to start the reaction. The
reaction proceeds in 10 ml according to the manufacturer’s
recommendations, in the presence of 0.3mM MgCl2,
0.1mM KCl. The naked oligonucleotide with free
imidazole (1:1 ratio) was used as a control. After 45min
at 308C, the translation levels were evaluated by Renilla
luciferase assays (Promega, France) using a microplate
luminometer (Centro XS3 LB960, Berthold, Germany).
The eﬀect of the ribonucleases was evaluated by compar-
ison of the Renilla luciferase activity in the absence and
presence of the conjugates. All the experiments were
performed in triplicates.
RESULTS
Influence of the cleaving group on the oligonucleotide
binding to the HCV IRESRNA
The binding aﬃnities of the four labelled conjugates for
increasing amounts of the complete IRES from HCV were
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assayed by native gel retardation assays and compared
to that of the naked oligonucleotide sequence (Figure 3a).
A retarded band (Figure 3a, star), not detected in the
control lane in the absence of the RNA, corresponds to
the RNA–conjugate complex. Two additional negative
controls were performed in the same conditions. First, we
incubated the HCV IRES with a non-speciﬁc oligonucleo-
tide (NS). This mismatched sequence does not bind
the IRES RNA, up to the higher concentration used for
the antisense oligonucleotide (data not shown). Then, the
ECMV IRES was incubated with the antisense (AS). No
retarded bands were detected (data not shown). The
apparent dissociation constants (Kd) of the HCV IRES-
oligonucleotide conjugates complex were calculated. The
uncoupled antisense oligonucleotide has a 70 nM appar-
ent Kd. Adding any of the three imidazole groups to the 30
or 50 end of the antisense oligonucleotide does not modify
signiﬁcantly this binding aﬃnity (data not shown).
According to its sequence, the antisense oligonucleotide
should bind to nucleotides 253 to 269 from domain IIId of
HCV IRES (Figure 1). RNase H experiments were carried
out to verify that the naked antisense oligonucleotide
as well as the four antisense conjugates bind at the
expected location, and not at additional ectopic sites
within the HCV IRES sequence. For all the ﬁve antisense
derivatives, RNase H-mediated cleavages are observed
at or around the expected location of pairing onto the
IRES RNA (Figure 3b, arrow and circles). Interestingly,
the 30-coupled imidazole conjugate 4 induces a cleavage of
the IRES next to the pairing area, whereas the other three
molecules trigger a cut within the pairing, which is
stronger for the 50-coupled urocanic acid 2 (Figure 3b).
Altogether, these results conﬁrm the speciﬁcity of the
antisense conjugates for their predicted binding site. The
50 or the 30 coupling of various chemicals do not aﬀect or
reduce binding speciﬁcity.
Targeted degradation of the HCV IRES by the DNA
conjugates
We designed and performed additional experiments, in
the absence of RNase H, in which the refolded IRES RNA
(Figure 1) is incubated from 5 to 60min with increasing
concentrations (from 0.5 to 50 mM) of either the naked
DNA antisense AS or the oligonucleotides conjugates 1 or
4. As negative controls, the naked antisense and the free,
uncoupled imidazole were used at concentrations and
incubation times identical to those used for the conjugates
(Material and Methods section). Alkaline hydrolysis and
RNase T1 and U2 digestions of the RNA allow the
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positioning of the cleavage sites. One-hour incubation
at the lower concentration (0.5 mM) is required to
observe a signiﬁcant cleavage at the expected location
(Figure 4, arrow) only for the 50-coupled imidazole
conjugate 1. Three strong additional cleavages are
observed for conjugates 1 and 4 (stars in Figure 4).
With the naked oligonucleotide AS, these cleavages are
very weak but can also be detected.
The cut triggered by the 50-coupled imidazole conjugate
1 occurs in stem IIId, between G271 and C272. These two
nucleotides are at the second and third positions after
the last nucleotide hybridized to the antisense sequence.
Despite a similar apparent binding constant for the IRES,
the 30-coupled imidazole conjugate 4 does not cleave at the
location predicted from base-pairing, even at the highest
concentration.
The three additional cleavages (Figure 4, stars), located
away from the binding sites of the complementary
sequence of the antisense within the IRES sequence, are
observed for all the conjugates, but not with free
imidazole. Of these three, two are heavy cuts, one
in domain IIIe between U297 and A298 (Figures 1 and
4, 1) and the other is between domains IIIa and IIIb,
between G171 and A172 (Figure 4, 2). The third weaker
cut is situated in domain IIIb between G181 and A182
(Figure 4, 3). Strikingly, whereas the 30-coupled imidazole
conjugate 4 does not induce a cleavage around its primary
recognition site, the binding to its target sequence within
the IRES structure is suﬃcient to induce the three
secondary cuts (Figure 4). This suggests that binding of
the conjugates is suﬃcient to modify the IRES structure
on a large scale that, in turn, reveals novel degradation
sites at speciﬁc locations.
Next, the inﬂuence of various conjugates on both the
site of cleavage and the eﬃciency of the RNA hydrolysis
was addressed. 50-coupling of either an urocanic acid or a
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Figure 4. In vitro cleavage assays between the conjugates and the IRES from HCV. Puriﬁed 30-labelled IRES is incubated with either 50 mM free
imidazole or increasing concentrations of the naked or the 30/50 imidazole-coupled antisense oligonucleotides for one hour at 378C. Partial RNA
sequencing using RNases T1 and U2 under denaturing conditions as well as partial alkaline RNA hydrolysis allows the mapping of the cleavage sites
within the IRES RNA sequence. The arrow points to the cleavage site, between G271 and C272, induced by conjugate 1. The stars point to three
additional cleavage sites induced by conjugates 1 and 4, mapped between U297 and A298 in domain IIIe (
1), between G171 and A172 between domains
IIIa and IIIb (2) and between G181 and A182 in domain IIIb (
3). Note that the two highest concentrations of the naked oligonucleotide elicit a weak
cleavage between G171 and A172 (
2).
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benzimidazoleacetic acid tests the inﬂuence of both
the pKa (benzimidazoleacetic acid, urocanic acid and
dihydrourocanic acid groups have pKas of 4.6, 5.3 and
6.95, respectively) and the ﬂexibility (benzimidazoleacetic
acid is the more rigid of the three because of a
phenyl group, urocanic acid is intermediate with one
double bond and dihydrourocanic acid is the more
ﬂexible, Figure 2). Neither the benzimidazoleacetic acid
3 nor the urocanic acid 2 conjugates elicit cleavage at
the location predicted from base-pairing, probably
because of their lower pKas and ﬂexibilities compared to
the dihydrourocanic acid conjugate 1 (data not shown).
Very weak secondary cuts 1 and 2 are induced by
conjugates 2 and 3 (data not shown).
Inhibition of HCV IRES-dependent translation by
the oligonucleotide conjugates
Translation assays were performed using a Renilla
luciferase reporter gene under the control of the HCV
IRES (Figures 5a and c) or the ECMV IRES (Figure 5b).
The IRES-Renilla luciferase RNA (IRES-RLuc) tran-
scripts were ﬁrst incubated with increasing concentrations
of the conjugates and then with the reticulocyte
lysate containing the ribosomes (see Material and
Methods section). The translation reactions were per-
formed for 45min, a time at which no RNA degradation
could be observed in the absence of the antisense
oligonucleotides (data not shown). The Renilla luciferase
protein levels were measured in the presence of the
conjugates and compared to those obtained in the absence
of the putative inhibitors. Direct comparisons between
the conjugates were inferred from the determination of
the concentration of the drug required to inhibit
reporter gene translation by half (IC50). As a control,
the eﬀect of a mismatched oligonucleotide (NS) was tested
and it doesn’t inhibit the translation of the HCV IRES
RNA (Figure 5a).
Long incubations of the IRES from HCV in a molar
imidazole buﬀer do not induce any RNA hydrolysis or
any detectable translation inhibition (not shown). Naked
oligonucleotide AS, from a 200 nM to a 5 mM concentra-
tion, reduces the rate of translation from 90 to 25%,
respectively, with a 1200 200 nM IC50. This suggests
that the uncoupled oligonucleotide already has substantial
inhibitory activity (Figure 5). Adding exogenous free
imidazole in a one-to-one ratio to the naked oligonucleo-
tide reduces the IC50 down to 900 200 nM.
Next, the ability of various concentrations of the
oligonucleotide conjugates to inhibit reporter gene trans-
lation was measured. The calculated IC50 of all the
oligonucleotides are listed in Table 1. Binding of each of
the conjugates to the IRES domain of this RNA
construct, followed by subsequent RNA hydrolysis,
reduces the expression of the reporter protein in a dose-
dependent manner (Figure 5a). Compared to the naked
oligonucleotide, the presence of a 30-coupled imidazole
slightly improves translation inhibition as when
free imidazole is added in the reaction buﬀer with the
naked antisense. Interestingly, the 50-coupled imidazole
conjugate 1 has 3-fold higher inhibition activity of the
IRES-driven reporter gene translation than the 30-coupled
imidazole 4 (Figure 5). The result is in agreement with
the fact that only the 50-conjugate 1 cleaves the IRES
sequence near its binding site in vitro and induces the
strongest speciﬁc degradation of the target (Figure 4). The
50-coupled imidazole conjugate 1 is the most powerful
inhibitor of HCV IRES-dependent translation, decreasing
the IC50 to 300 100 nM, a 4-fold diﬀerence compared
to the naked oligonucleotide AS. When modifying the
cleaving group, neither the urocanic acid conjugate 2
nor the benzimidazoleacetic acid conjugate 3 improved
the IC50 of the 50-coupled imidazole 1 (Figure 5). The
50-coupled benzimidazoleacetic acid conjugate 3 is none-
theless an interesting conjugate, lowering the IC50 3-fold
compared to the naked oligonucleotide AS. To conﬁrm
the speciﬁcity of translation inhibition of the conjugates
on the IRES from HCV, similar experiments were carried
out on the IRES from ECMV by using all the conjugates
and the naked oligonucleotide (Figure 5b). Within the
same concentration range, no signiﬁcant inhibitory eﬀect
on translation could be detected.
Due to the results obtained with the 50-imidazole
coupled DNA antisense oligonucleotide 1, we coupled
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Figure 5. Dose-dependent inhibition of viral protein synthesis by the
DNA conjugates in vitro. The translation assays were performed at 308C
for 45min. The Renilla luciferase protein levels measured in the presence
of each conjugates were all divided by the protein level obtained in the
absence of translation inhibitors. (a) Concentration-dependent viral
translation inhibition of the HCV-IRES RNA by the non-speciﬁc
oligonucleotide NS, the naked DNA antisense AS, the ‘naked-free
imidazole’ in a one-to-one ratio or the 30- or the 50-imidazole-coupled
oligonucleotides 4 and 1. (b) translation inhibition of the ECMV-IRES
RNA by the naked (AS), the 30- or the 50-imidazole-coupled oligonucleo-
tides 4 and 1. (c) Concentration-dependent translation inhibition of the
HCV-IRES RNA by the naked 20-O-Me RNA antisense RNA_AS or the
50-imidazole-coupled 20-O-Me-RNA oligonucleotides 5.
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an imidazole moiety at the 50-end of the 20-O-Me-RNA
antisense. Despite the signiﬁcant decrease of the IC50 that
could be observed when adding an imidazole at the 50-end
of the DNA antisense, no decrease of the IC50 could be
observed when adding an imidazole at the 50-end of the
antisense RNA.
DISCUSSION
In this report, novel oligonucleotide conjugates containing
imidazole groups were designed to target and cleave
the IIId domain of the HCV Internal Ribosome Entry
Site (IRES) with speciﬁcity, aﬃnity and eﬃciency. The
antisense oligonucleotide sequence is complementary to
nucleotides 253 to 269 from hairpin IIId of the IRES from
HCV; it binds to the HCV IRES at its expected location
and inhibits cap-independent IRES-mediated translation
(21). This oligonucleotide sequence is speciﬁc of the HCV-
IRES RNA and, as a negative control, it could not bind or
inhibit the ECMV IRES.
Oligomers that pair with domain IIId of the IRES from
HCV have been selected by various methods and all are
potent inhibitors of viral translation in vitro (20,21,28,39).
Interestingly, all contain a 50ACCCAA30sequence that can
pair with the 50264UUGGGU2693
0 sequence from loop
IIId, probably important to initiate pairing between the
oligonucleotide and its RNA target. To improve the
ability of the oligonucleotide to inhibit IRES-mediated
translation, imidazole derivatives were coupled ﬁrst to the
DNA sequence, then to its 20-O-Me-RNA analogue,
reasoning that if speciﬁc cleavages of the IRES RNA
can be triggered at the vicinity of the antisense binding
site, it may increase further the inhibition of translation
initiation.
The RNA-cleaving group could be coupled at either
the 50 or the 30 end of the oligonucleotide sequence. The
50-imidazole conjugate 1 induces cleavage of the IRES
between nts G271 and C272, two nucleotides away from the
last 50-paired nt (Figure 4) and decreases translation 4-fold
compared to the naked oligonucleotide (the IC50 goes
from 1200 200 nM for the naked oligonucleotide AS to
300 100 nM for the conjugate 1 (Table 1). The conjugate
1 has the highest eﬃciency to cleave the IRES RNA
in vitro and is also the most potent inhibitor of viral
translation. The IC50 of the naked antisense into
an imidazole buﬀer is three-times higher than that of the
50-imidazole conjugate 1, suggesting that the higher
activity of the latter comes from the higher local
concentration of the cleaving group in the vicinity of the
RNA backbone. The 30-imidazole conjugate 4 is not able
to cleave around its binding site, even at a 50 mM
concentration (Figure 4). Both the 50 and the 30 conjugates
place their RNA-cleaving groups next to paired regions,
C270–A274 for the 5
0-conjugate and A244–A252 for the
30-conjugate, that are less favourable for RNA hydrolysis
than RNA single-strands. The short (5 bp) stem near
the imidazole moiety of 50-conjugate probably allows
suﬃcient ﬂexibility of the ribose-phosphate chain for
imidazole-induced RNA hydrolysis, whereas the nine
base-paired helix next to the imidazole moiety of the
30-conjugate is probably too rigid to allow acid-base
catalysis to occur (Figure 1). The cleavage of the
phosphodiester backbone of an RNA by an imidazole
moiety generally involves two imidazoles, one acting as a
base and the other one as an acid. However, the 50-coupled
imidazole oligonucleotide 1 that speciﬁcally cleaves the
HCV-IRES RNA bears only one imidazole. One explana-
tion could involve the divalent metal ions contained in the
cleavage buﬀer. Indeed, divalent metal cations such as
Mg2+ and Zn2+ can act as a Lewis acid (40), thus
contributing to the cleavage mechanism of the ribonucleic
chain by a single imidazole. In a second time, the 50-
imidazole cleaving group was replaced by a benzimidazo-
leacetic acid 3, or by an urocanic acid 2. These two
functional groups are more rigid and have lower pKas
than an imidazole. None of these two conjugates induce
speciﬁc cleavage of the HCV-IRES RNA at the vicinity of
its binding site within the IRES. Therefore, we can
conclude that lowering both the pKas and the ﬂexibility
of the cleaving group inhibit RNA hydrolysis. The best
results were obtained with an imidazole coupled at the
50-end of the AS sequence. Note that the use of a 20-O-Me
RNA antisense sequence increases the overall inhibitory
eﬀect of the naked compound, but is not further improved
by the addition of an imidazole. The aﬃnity of the 20-O-
Me RNA antisense for the IRES RNA is about 2 nM (21).
It is 35-fold higher than the aﬃnity of the DNA antisense
AS (apparent Kd of 70 nM). The high aﬃnity of the
antisense RNA for the IRES makes an important
contribution for translation inhibition. The lack of
improvement that we observe when we couple an
imidazole at the 50-end of a 20-O-Me RNA antisense is
probably due to this increased aﬃnity that takes over the
inﬂuence of the imidazole.
Interestingly, additional cleavages, away from the
oligonucleotide recognition sequence and also distant
one another onto the IRES secondary structure
(Figure 1, stars), were consistently observed. These
cleavages can be weakly observed with the naked antisense
oligonucleotide AS. They are signiﬁcantly increased
with both the 50- and the 30-imidazole conjugates
(Figure 4). These three sites were mapped by partial
RNA sequencing between U297 and A298 in domain IIIe
(1) between G171 and A172 (2
) between domains IIIa
Table 1. Concentration at which translation is reduced by half (IC50)
Oligonucleotide IC50 (mM)
AS 1.2 0.2
Imidazole+AS (1:1) 0.9 0.2
50-Imidazole (1) 0.3 0.1
50-UA (2) 0.8 0.2
50-BI (3) 0.4 0.1
30-Imidazole (4) 0.9 0.2
RNA_AS 0.10 0.02
50-Imidazole RNA (5) 0.09 0.03
The IC50 has been calculated for either the naked antisense or the
conjugates the DNA-conjugates 1–4 and for the 20-O-Me-RNA
oligonucleotides, naked RNA_AS or conjugate 5. These data were
derived from at least three independent experiments. Concerning the
inhibition of the ECMV-IRES RNA by the DNA conjugates, the IC50
could not be determined.
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and IIIb and between G181 and A182 (3
) in domain IIIb.
These additional cuts remove the essential domains IIIb to
IIIe from the IRES (Figure 1), most likely aﬀecting
the recognition of the IRES by eIF3 (Figure 6c) and
possibly also its interaction with the 40S subunit
(Figure 6b). These data are a reasonable explanation as
to why a dose-dependent IRES-mediated translation
inhibition is detected in vitro. A cryo-EM structural
model of the IRES locked on a translation initiation
state in complex with eIF3 and the 40S subunit (13) shows
that the additional cleavage sites are far away when
looking at the primary sequence but are clustered around
the nucleotide recognition sequence on the IRES three-
dimensional structure derived from cryo-EM (Figure 6c,
blue stars). In the context of the naked IRES tertiary
structure, those three cleavages may even be closer one
another. Upon binding of the 50 or the 30 complementary
oligonucleotide, the IRES structure may adopt alternate
conformation(s) that, in turn, become(s) hydrolysed at
additional secondary sites. This conformational change
is speciﬁc since only three additional cleavages sites
are observed. The respective contribution of the RNA
hydrolysis versus the trigger of an inactive conformation
of the IRES in the overall translation inhibition observed
in vitro is unknown. Both the sequence and structure of
domain III from the IRES are essential for the binding of
eIF3 (3,16,41,42) and of ribosomal protein S9 (43).
Interestingly, this is particularly true for domains IIIb
and IIId (44), which are both cleaved by conjugate 1.
The interaction of domain IIId with the 40S ribosomal
subunit and eIF3 makes this RNA module an attracting
target for blocking translation initiation of the viral
proteins. We believe that this work is original and
promising because the functional eﬀects on IRES-depen-
dent translation of each of the molecules synthesized could
be analysed according to their potential for IRES RNA
hydrolysis. These novel conjugates are active at low
concentrations, require short (<1 h) incubation times
and inhibit IRES-dependent translation in vitro in a
dose-dependent manner. These novel molecules capable of
directed degradation of a functional domain of HCV
genomic RNA are now being tested for antiviral activity
and toxicity in in vitro-infected cells.
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